Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang
Immix Biopharma (NASDAQ:IMMX), a clinical-stage biopharmaceutical company, has secured a strategic investment from Goose Capital, led by former Tanox CEO Dr. Nancy T. Chang. Dr. Chang's track record includes developing successful FDA-approved drugs like 齿翱尝础滨搁庐, 罢搁翱骋础搁窜翱庐, and 贰叠骋尝驰厂厂庐, which have collectively generated over $5 billion in sales.
The investment aims to support Immix's development of cell therapies for AL Amyloidosis and other serious diseases, particularly the commercialization of NXC-201 for relapsed/refractory AL Amyloidosis. This strategic partnership brings valuable expertise to Immix, as Dr. Chang has significant experience in bringing drugs from invention through FDA approval and commercialization.
Immix Biopharma (NASDAQ:IMMX), azienda biofarmaceutica in fase clinica, ha ottenuto un investimento strategico da Goose Capital, guidato dall鈥檈x amministratore delegato di Tanox, la dott.ssa Nancy T. Chang. La dott.ssa Chang vanta un curriculum che comprende lo sviluppo di farmaci approvati dalla FDA come 齿翱尝础滨搁庐, 罢搁翱骋础搁窜翱庐 e 贰叠骋尝驰厂厂庐, che insieme hanno generato oltre 5 miliardi di dollari di vendite.
L鈥檌nvestimento 猫 finalizzato a sostenere lo sviluppo da parte di Immix di terapie cellulari per l鈥檃miloidosi AL e altre patologie gravi, con particolare attenzione alla commercializzazione di NXC-201 per l鈥檃miloidosi AL recidivante/refrattaria. Questa collaborazione strategica apporta a Immix l鈥檈sperienza preziosa della dott.ssa Chang nel portare farmaci dall鈥檌nvenzione all鈥檃pprovazione FDA e alla commercializzazione.
Immix Biopharma (NASDAQ:IMMX), una compa帽铆a biofarmac茅utica en fase cl铆nica, ha asegurado una inversi贸n estrat茅gica de Goose Capital, liderada por la ex directora ejecutiva de Tanox, la Dra. Nancy T. Chang. La Dra. Chang cuenta con un historial que incluye el desarrollo de f谩rmacos aprobados por la FDA como 齿翱尝础滨搁庐, 罢搁翱骋础搁窜翱庐 y 贰叠骋尝驰厂厂庐, que en conjunto han generado m谩s de 5.000 millones de d贸lares en ventas.
La inversi贸n tiene como objetivo apoyar el desarrollo por parte de Immix de terapias celulares para la amiloidosis AL y otras enfermedades graves, en particular la comercializaci贸n de NXC-201 para la amiloidosis AL en reca铆da/refractaria. Esta asociaci贸n estrat茅gica aporta a Immix la valiosa experiencia de la Dra. Chang en llevar medicamentos desde la invenci贸n hasta la aprobaci贸n por la FDA y su comercializaci贸n.
Immix Biopharma (NASDAQ:IMMX), 鞛勳儊 雼硠鞚� 氚旍澊鞓れ牅鞎� 須岇偓臧� 鞝� Tanox CEO鞚� 鞛ル倻鞁�(Dr. Nancy T. Chang)臧� 鞚措亜電� Goose Capital搿滊秬韯� 鞝勲灥鞝� 韴瀽毳� 鞙犾箻頄堨姷雼堧嫟. 鞛� 氚曥偓電� 齿翱尝础滨搁庐, 罢搁翱骋础搁窜翱庐, 贰叠骋尝驰厂厂庐鞕� 臧欖澊 FDA 鞀轨澑鞚� 氚涭潃 鞎诫 臧滊皽 鞚措牓鞚� 臧�歆�瓿� 鞛堨溂氅�, 鞚措摛 鞎诫鞚� 頃╈硱靹� 50鞏� 雼煬 鞚挫儊鞚� 毵れ稖鞚� 鞓牳鞀惦媹雼�.
鞚措矆 韴瀽電� AL 鞎勲皜搿滌澊霌滌 氚� 旮绊儉 欷戩 歆堩櫂鞐� 雽�頃� 靹疙彫 旃橂鞝� 臧滊皽, 韸鬼瀳 鞛皽/攵堨潙靹� AL 鞎勲皜搿滌澊霌滌 旃橂鞖� NXC-201鞚� 靸侅梾頇旊ゼ 歆�鞗愴晿旮� 鞙勴暅 瓴冹瀰雼堧嫟. 鞚� 鞝勲灥鞝� 韺岉姼雱堨嫮鞚� 氚滊獏 雼硠攵�韯� FDA 鞀轨澑 氚� 靸侅梾頇旉箤歆�鞚� 瓴巾棙鞚� 頀嶋秬頃� 鞛� 氚曥偓鞚� 鞝勲靹膘潉 Immix鞐� 鞝滉车頃╇媹雼�.
Immix Biopharma (NASDAQ:IMMX), une soci茅t茅 biopharmaceutique en phase clinique, a obtenu un investissement strat茅gique de Goose Capital, dirig茅 par l鈥檃ncienne PDG de Tanox, la Dre Nancy T. Chang. La Dre Chang a fait ses preuves en d茅veloppant des m茅dicaments approuv茅s par la FDA tels que 齿翱尝础滨搁庐, 罢搁翱骋础搁窜翱庐 et 贰叠骋尝驰厂厂庐, qui ont g茅n茅r茅 ensemble plus de 5 milliards de dollars de ventes.
Cet investissement vise 脿 soutenir le d茅veloppement par Immix de th茅rapies cellulaires pour l鈥檃mylose AL et d鈥檃utres maladies graves, en particulier la commercialisation de NXC-201 pour l鈥檃mylose AL r茅currente/r茅fractaire. Ce partenariat strat茅gique apporte 脿 Immix l鈥檈xp茅rience pr茅cieuse de la Dre Chang pour accompagner des m茅dicaments de l鈥檌nvention 脿 l鈥檃pprobation par la FDA et 脿 la mise sur le march茅.
Immix Biopharma (NASDAQ:IMMX), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat eine strategische Investition von Goose Capital erhalten, geleitet von der ehemaligen Tanox-CEO Dr. Nancy T. Chang. Dr. Chang verf眉gt 眉ber Erfolge bei der Entwicklung von FDA-zugelassenen Medikamenten wie 齿翱尝础滨搁庐, 罢搁翱骋础搁窜翱庐 und 贰叠骋尝驰厂厂庐, die zusammen mehr als 5 Milliarden US-Dollar Umsatz erzielt haben.
Die Investition soll Immix bei der Entwicklung von Zelltherapien f眉r AL-Amyloidose und andere schwere Erkrankungen unterst眉tzen, insbesondere bei der Kommerzialisierung von NXC-201 f眉r rezidivierende/refrakt盲re AL-Amyloidose. Die strategische Partnerschaft bringt Immix die wertvolle Erfahrung von Dr. Chang bei der Begleitung von Medikamenten von der Erfindung 眉ber die FDA-Zulassung bis zur Vermarktung.
- Strategic investment secured from experienced biotech investor Goose Capital
- Partnership with Dr. Nancy T. Chang, who has track record of developing drugs with $5B+ in sales
- Addition of valuable expertise in FDA approval and drug commercialization process
- Early clinical-stage company with no approved products yet
- Specific investment amount not disclosed
Insights
Goose Capital's strategic investment in Immix Biopharma brings valuable industry validation and expertise for NXC-201's commercialization in AL Amyloidosis.
The strategic investment from Goose Capital into Immix Biopharma (
This partnership brings more than just capital. Dr. Chang's experience in successfully navigating the FDA approval process and commercializing breakthrough treatments aligns perfectly with Immix's development of NXC-201 for relapsed/refractory AL Amyloidosis. AL Amyloidosis represents a significant unmet medical need, characterized by protein deposits that damage organs and tissues, with limited effective treatment options currently available.
The investment follows what Goose Capital describes as a "deep evaluation" of Immix's technology, team, and target market, suggesting thorough due diligence was performed before committing resources. This external validation from experienced biotech investors strengthens Immix's position as it works toward commercialization.
While the financial terms of the investment weren't disclosed, the strategic nature of this partnership likely provides Immix with additional industry connections and expertise that could accelerate their clinical development timeline and enhance their commercialization strategy for NXC-201 and other potential therapies in their pipeline.
LOS ANGELES, CA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (鈥淚mmix鈥�, 鈥淐ompany鈥�, 鈥淲e鈥� or 鈥淯s鈥� or 鈥滻MMX鈥�), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it has received a strategic investment from Goose Capital and former Tanox, Inc. CEO Dr. Nancy T. Chang, Goose founding member.
At Tanox, Dr. Chang and her team invented and developed FDA-approved 齿翱尝础滨搁庐 (omalizumab) for severe asthma, 罢搁翱骋础搁窜翱庐 (ibalizumab-uiyk) for HIV, and 贰叠骋尝驰厂厂庐 (lebrikizumab-lbkz) for dermatitis, collectively generating drug sales exceeding 5 billion dollars so far. Tanox, Inc. was acquired by Genentech/Roche. 贰叠骋尝驰厂厂庐 is commercialized by Eli Lilly and Co.
鈥淚mmix鈥檚 mission of curing the incurable resonates with Goose鈥檚 goal of investing in breakthrough technologies and innovative founders to forge the future of human medicine,鈥� said Anthony George, President of Goose Capital. Ashok Rao, Board Member of Goose Capital, added, 鈥淎fter a deep evaluation of the technology, team, and market that Immix is pursuing, we are pleased to support, and anticipate exciting progress to-come.鈥�
鈥淲e are thrilled that Dr. Chang and Goose recognize the opportunity for commercialization of NXC-201 in relapsed/refractory AL Amyloidosis, other serious diseases, and beyond,鈥� said Ilya Rachman, M.D., Ph.D., Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, added, 鈥淕oose and Dr. Chang bring unparalleled experience to the Immix team. Dr. Chang led 齿翱尝础滨搁庐 from invention through FDA approval and commercialization, further enabling our goal to deliver widely accessible cures, as patients are waiting.鈥�
About Goose Capital
Goose Capital is an investment firm comprised of former Fortune 500 executives, industry leaders, and serial entrepreneurs. Goose Capital invests in breakthrough technologies, early-stage startups and innovative founders.
About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a 鈥渄igital filter鈥� that filters out non-specific activation. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design. NEXICART-2 primary endpoint was met at interim results presented at ASCO 2025. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA. Learn more at www.immixbio.com and www.BeProactiveInAL.com.
Forward Looking Statements
This press release contains forward-looking statements regarding Immix Biopharma, Inc., its results of operations, prospects, future business plans and operations and the matters discussed above, including, but not limited to, the potential benefits of our product candidate CAR-T NXC-201 and the timing and results related clinical trials. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements also include, but are not limited to, our plans, objectives, expectations and intentions and other statements that contain words such as 鈥渆xpects鈥�, 鈥渃ontemplates鈥�, 鈥渁nticipates鈥�, 鈥減lans鈥�, 鈥渋ntends鈥�, 鈥渂elieves鈥�, 鈥渆stimates鈥�, 鈥減otential鈥�, and variations of such words or similar expressions that convey the uncertainty of future events or outcomes, or that do not relate to historical matters. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the further data from the ongoing Phase 1/2 clinical trials for CAR-T NXC-201 will not be favorably consistent with the data readouts to date, (ii) the risk that the Company may not be able to continue the NEXICART-2 multi-site U.S. Phase 1/2 clinical trial; (iii) the risk that the Company may not be able to advance to registration-enabling studies for CAR-T NXC-201 or other product candidates, (iv) that success in early phases of pre-clinical and clinicals trials do not ensure later clinical trials will be successful; (v) that no drug product developed by the Company has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (vi) the risk that the Company may not be able to obtain additional working capital with which to continue the clinical trials for CAR-T NXC-201, or advance to the initiation of registration-enabling studies, for such product candidates as and when needed and (vii) those other risks disclosed in the section 鈥淩isk Factors鈥� included in the Company鈥檚 Annual Report on Form 10-K filed with the SEC on March 25, 2025 and other periodic reports subsequently filed with the Securities and Exchange Commission. These reports are available at www.sec.gov. Immix Biopharma cautions that the foregoing list of important factors is not complete. Immix Biopharma cautions readers not to place undue reliance on any forward-looking statements. Immix Biopharma does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Contacts
Mike Moyer
LifeSci Advisors
[email protected]
Company Contact
[email protected]
FAQ
What is the strategic investment Immix Biopharma (IMMX) received in September 2025?
Who is Dr. Nancy T. Chang and why is her involvement significant for IMMX?
What is Immix Biopharma's main development focus?
How does this investment align with Goose Capital's investment strategy?
